This document outlines a study investigating the effects of statin drugs like Simvastatin on the gut microbiome in relation to clinical obesity. The hypothesis is that certain statins will selectively inhibit bacteria in the Fimicutes phylum, which are more prevalent in obese individuals. The methods test the susceptibility of various bacterial species to different statins in vitro. Results show the statins had varying effects, with some inhibiting Clostridium species. Future experiments will examine changes in fecal microbiome DNA from patients taking Simvastatin.